These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32436254)

  • 1. Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.
    Oliva Arguelles B; Riera-Romo M; Guerra Vallespi M
    Br J Pharmacol; 2020 Aug; 177(16):3625-3634. PubMed ID: 32436254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
    Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
    J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1.
    Daghero H; Fernández Massó JR; Astrada S; Guerra Vallespí M; Bollati-Fogolín M
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552.
    Vallespi MG; Rodriguez JC; Seoane LC; Alvarez P; Santana H; Garay H; Cabrera IA; Espinosa JT; Reyes O
    Res Vet Sci; 2017 Oct; 114():502-510. PubMed ID: 28987957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity.
    Astrada S; Fernández Massó JR; Vallespí MG; Bollati-Fogolín M
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29601540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552.
    Astrada S; Gomez Y; Barrera E; Obal G; Pritsch O; Pantano S; Vallespí MG; Bollati-Fogolín M
    J Pept Sci; 2016 Nov; 22(11-12):711-722. PubMed ID: 27933724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
    Vallespi MG; Mestre B; Marrero MA; Uranga R; Rey D; Lugiollo M; Betancourt M; Silva K; Corrales D; Lamadrid Y; Rodriguez Y; Maceo A; Chaviano PP; Lemos G; Cabrales A; Freyre FM; Santana H; Garay HE; Oliva B; Fernandez JR
    Int J Cancer; 2021 Sep; 149(6):1313-1321. PubMed ID: 34019700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models.
    Gomez Rodriguez Y; Oliva Arguelles B; Riera-Romo M; Fernandez-De-Cossio J; Garay HE; Fernandez Masso J; Guerra Vallespi M
    Mol Biol Rep; 2022 Apr; 49(4):3197-3212. PubMed ID: 35094208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
    Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ
    J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.
    Fernández Massó JR; Oliva Argüelles B; Tejeda Y; Astrada S; Garay H; Reyes O; Delgado-Roche L; Bollati-Fogolín M; Vallespí MG
    J Amino Acids; 2013; 2013():251398. PubMed ID: 23401744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic Study to Survey the CIGB-552 Antitumor Effect.
    Rodríguez-Ulloa A; Gil J; Ramos Y; Hernández-Álvarez L; Flores L; Oliva B; García D; Sánchez-Puente A; Musacchio-Lasa A; Fernández-de-Cossio J; Padrón G; González López LJ; Besada V; Guerra-Vallespí M
    Biomed Res Int; 2015; 2015():124082. PubMed ID: 26576414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells.
    Núñez de Villavicencio-Díaz T; Ramos Gómez Y; Oliva Argüelles B; Fernández Masso JR; Rodríguez-Ulloa A; Cruz García Y; Guirola-Cruz O; Perez-Riverol Y; Javier González L; Tiscornia I; Victoria S; Bollati-Fogolín M; Besada Pérez V; Guerra Vallespi M
    J Proteomics; 2015 Aug; 126():163-71. PubMed ID: 26013411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
    Perea SE; Baladrón I; Valenzuela C; Perera Y
    Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
    Perera Y; Costales HC; Diaz Y; Reyes O; Farina HG; Mendez L; Gómez RE; Acevedo BE; Gomez DE; Alonso DF; Perea SE
    J Pept Sci; 2012 Apr; 18(4):215-23. PubMed ID: 22407768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
    Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
    Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
    Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
    Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.
    Rodríguez-Ulloa A; Ramos Y; Gil J; Perera Y; Castellanos-Serra L; García Y; Betancourt L; Besada V; González LJ; Fernández-de-Cossio J; Sanchez A; Serrano JM; Farina H; Alonso DF; Acevedo BE; Padrón G; Musacchio A; Perea SE
    J Proteome Res; 2010 Oct; 9(10):5473-83. PubMed ID: 20804217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.
    Benavent Acero FR; Perera Negrin Y; Alonso DF; Perea SE; Gomez DE; Farina HG
    Mol Pharm; 2014 Jun; 11(6):1798-807. PubMed ID: 24773585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic Analogues of Horseshoe Crab Peptide Tachyplesin I with Anticancer and Cell Penetrating Properties.
    Vernen F; Craik DJ; Lawrence N; Troeira Henriques S
    ACS Chem Biol; 2019 Dec; 14(12):2895-2908. PubMed ID: 31714739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
    Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.